CompletedPhase 2NCT00002970

506U78 in Treating Patients With Refractory Hematologic Cancer

Studying Acute graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Stacey Berg
Children's Oncology Group
Intervention
nelarabine(drug)
Enrollment
148 enrolled
Eligibility
21 years · All sexes
Timeline
1997

Study locations (1)

Collaborators

Children's Cancer Group

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00002970 on ClinicalTrials.gov

Other trials for Acute graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Acute graft versus host disease

← Back to all trials